Full Text View
Tabular View
No Study Results Posted
Related Studies
The Effect of 0.5% Roxithromycin Lotion for Androgenetic Alopecia
This study is ongoing, but not recruiting participants.
Study NCT00197379   Information provided by Hamamatsu University
First Received: September 12, 2005   Last Updated: October 30, 2007   History of Changes

September 12, 2005
October 30, 2007
May 2005
 
 
The hair elongation after 1 week of application. Cosmetical improvement. Evaluation by dermoscopy
Complete list of historical versions of study NCT00197379 on ClinicalTrials.gov Archive Site
Pathological study taken from lesional scalp skin. [ Time Frame: One year ]
Pathological study taken from lesional scalp skin.
 
The Effect of 0.5% Roxithromycin Lotion for Androgenetic Alopecia
The Study for New Effect of Roxithromycin on Androgenetic Alopecia.

The purpose of this study is exploiting the new drugs for androgenetic alopecia because there are still no effective and safe topical drug for androgenetic alopecia. Roxithomycin is one of the macrolide antibiotics that has immunomodulatory effects. We firstly found that roxithromycin increases the rate of murine and human hair follicle elongation in vitro. Therefore, we apply this drug on this disease therapy.

The topical therapy for androgenetic alopecia is still not enough to improve cosmetically. Thereforem we try to find new effective and safe topical therapy for this disease. Roxithromycin has not only antibacterial action but also immunomodulatory and anti-inflamatory potency. For example, roxitromycin inhibits T cell responces to mitogens and production of cytokines, IL-2 and IL-5. We firstly found that roxitromycin increased human and murine hair elongation in vitro to inhibit apoptosis of hair bulb. Then, we wish to apply roxithromycin on the therapy for androgenetic alopecia.

 
Interventional
Treatment, Randomized, Open Label, Placebo Control, Crossover Assignment, Safety/Efficacy Study
Alopecia
Drug: roxithromycin
 

*   Includes publications given by the data provider as well as publications identified by National Clinical Trials Identifier (NCT ID) in Medline.
 
Active, not recruiting
20
January 2007
 

Inclusion Criteria:

  • Androgenetic alopecia

Exclusion Criteria:

  • Cicatricial alopecia
  • Allergy to roxitromycin
  • Children (19years old or younger)
  • Pregnant female
Both
20 Years and older
Yes
Contact information is only displayed when the study is recruiting subjects
Japan
 
NCT00197379
 
16-61
Hamamatsu University
 
Study Chair: Masahiro Takigawa, M.D. Hamamatsu University
Hamamatsu University
April 2005

ICMJE     Data element required by the International Committee of Medical Journal Editors and the World Health Organization ICTRP